Home / Health / Bristol Myers' Cell Therapy Shows Promise in Blood Cancer Trial
Bristol Myers' Cell Therapy Shows Promise in Blood Cancer Trial
8 Sep
Summary
- Experimental cell therapy arlo-cel tested for hard-to-treat multiple myeloma.
- Mid-stage trial met main goal, showing significant patient response.
- Secondary goal achieved with complete cancer remission in more patients.
Bristol Myers Squibb has reported promising outcomes from a mid-stage clinical trial involving its experimental cell therapy, known as arlocabtagene autoleucel or arlo-cel.
This therapy is under evaluation for patients diagnosed with a challenging form of multiple myeloma, a type of blood cancer.
The trial achieved its primary objective, demonstrating a significant increase in the percentage of participants who responded positively to the treatment.
Additionally, a crucial secondary goal was met. This involved a greater number of patients achieving a complete response, signifying the complete eradication of cancer signs post-treatment.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
